Skip to main content

Engineering Enhanced Immunogenicity of Surface-Displayed Immunogens in a Killed Whole-Cell Genome-Reduced Bacterial Vaccine Platform Using Class I Viral Fusion Peptides.

Journal articles  - Journal Article
Quintero-Barbosa, JS; Song, Y; Mehl, F; Mathur, S; Livingston, L; Shen, X; Montefiori, DC; Tan, J; Zeichner, SL
Published in: Vaccines (Basel)
December 22, 2025

Background/Objectives: New vaccine platforms that rapidly yield low-cost, easily manufactured vaccines are highly desired, yet current approaches lack key features. We developed the Killed Whole-Cell/Genome-Reduced Bacteria (KWC/GRB) platform, which uses a genome-reduced Gram-negative chassis to enhance antigen exposure and modularity via an autotransporter (AT) system. Integrated within a Design-Build-Test-Learn (DBTL) framework, KWC/GRB enables rapid iteration of engineered antigens and immunomodulatory elements. Here, we applied this platform to the HIV-1 fusion peptide (FP) and tested multiple antigen engineering strategies to enhance its immunogenicity. Methods: For a new vaccine, we synthesized DNA encoding the antigen together with selected immunomodulators and cloned the constructs into a plasmid. The plasmids were transformed into genome-reduced bacteria (GRB), which were grown, induced for antigen expression, and then inactivated to produce the vaccines. We tested multiple strategies to enhance antigen immunogenicity, including multimeric HIV-1 fusion peptide (FP) designs separated by different linkers and constructs incorporating immunomodulators such as TLR agonists, mucosal-immunity-promoting peptides, and a non-cognate T-cell agonist. Vaccines were selected based on structure prediction and confirmed surface expression by flow cytometry. Mice were vaccinated, and anti-FP antibody responses were measured by ELISA. Results: ELISA responses increased nearly one order of magnitude across design rounds, with the top-performing construct showing an ~8-fold improvement over the initial 1mer vaccine. Multimeric antigens separated by an α-helical linker were the most immunogenic. The non-cognate T-cell agonist increased responses context-dependently. Flow cytometry showed that increased anti-FP-mAb binding to GRB was associated with greater induction of antibody responses. Although anti-FP immune responses were greatly increased, the sera did not neutralize HIV. Conclusions: Although none of the constructs elicited detectable neutralizing activity, the combination of uniformly low AlphaFold pLDDT scores and the functional data suggests that the FP region may not adopt a stable native-like structure in this display context. Importantly, the results demonstrate that the KWC/GRB platform can generate highly immunogenic vaccines, and when applied to antigens with well-defined native tertiary structures, the approach should enable rapidly produced, high-response, very low-cost vaccines.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Vaccines (Basel)

DOI

ISSN

2076-393X

Publication Date

December 22, 2025

Volume

14

Issue

1

Location

Switzerland

Related Subject Headings

  • 3207 Medical microbiology
  • 3204 Immunology
  • 3202 Clinical sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Quintero-Barbosa, J. S., Song, Y., Mehl, F., Mathur, S., Livingston, L., Shen, X., … Zeichner, S. L. (2025). Engineering Enhanced Immunogenicity of Surface-Displayed Immunogens in a Killed Whole-Cell Genome-Reduced Bacterial Vaccine Platform Using Class I Viral Fusion Peptides. Vaccines (Basel), 14(1). https://doi.org/10.3390/vaccines14010014
Quintero-Barbosa, Juan Sebastian, Yufeng Song, Frances Mehl, Shubham Mathur, Lauren Livingston, Xiaoying Shen, David C. Montefiori, Joshua Tan, and Steven L. Zeichner. “Engineering Enhanced Immunogenicity of Surface-Displayed Immunogens in a Killed Whole-Cell Genome-Reduced Bacterial Vaccine Platform Using Class I Viral Fusion Peptides.Vaccines (Basel) 14, no. 1 (December 22, 2025). https://doi.org/10.3390/vaccines14010014.
Quintero-Barbosa JS, Song Y, Mehl F, Mathur S, Livingston L, Shen X, et al. Engineering Enhanced Immunogenicity of Surface-Displayed Immunogens in a Killed Whole-Cell Genome-Reduced Bacterial Vaccine Platform Using Class I Viral Fusion Peptides. Vaccines (Basel). 2025 Dec 22;14(1).
Quintero-Barbosa, Juan Sebastian, et al. “Engineering Enhanced Immunogenicity of Surface-Displayed Immunogens in a Killed Whole-Cell Genome-Reduced Bacterial Vaccine Platform Using Class I Viral Fusion Peptides.Vaccines (Basel), vol. 14, no. 1, Dec. 2025. Pubmed, doi:10.3390/vaccines14010014.
Quintero-Barbosa JS, Song Y, Mehl F, Mathur S, Livingston L, Shen X, Montefiori DC, Tan J, Zeichner SL. Engineering Enhanced Immunogenicity of Surface-Displayed Immunogens in a Killed Whole-Cell Genome-Reduced Bacterial Vaccine Platform Using Class I Viral Fusion Peptides. Vaccines (Basel). 2025 Dec 22;14(1).

Published In

Vaccines (Basel)

DOI

ISSN

2076-393X

Publication Date

December 22, 2025

Volume

14

Issue

1

Location

Switzerland

Related Subject Headings

  • 3207 Medical microbiology
  • 3204 Immunology
  • 3202 Clinical sciences